APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
3
Issued Date
2024-01-01
Resource Type
ISSN
19360533
eISSN
19360541
Scopus ID
2-s2.0-85209718693
Journal Title
Hepatology International
Rights Holder(s)
SCOPUS
Bibliographic Citation
Hepatology International (2024)
Suggested Citation
Lau G., Obi S., Zhou J., Tateishi R., Qin S., Zhao H., Otsuka M., Ogasawara S., George J., Chow P.K.H., Cai J., Shiina S., Kato N., Yokosuka O., Oura K., Yau T., Chan S.L., Kuang M., Ueno Y., Chen M., Cheng A.L., Cheng G., Chuang W.L., Baatarkhuu O., Bi F., Dan Y.Y., Gani R.A., Tanaka A., Jafri W., Jia J.D., Kao J.H., Hasegawa K., Lau P., Lee J.M., Liang J., Liu Z., Lu Y., Pan H., Payawal D.A., Rahman S., Seong J., Shen F., Shiha G., Song T., Sun H.C., Masaki T., Sirachainan E., Wei L., Yang J.M., Sallano J.D., Zhang Y., Tanwandee T., Dokmeci A., Zheng S.S., fan J., Fan S.T., Sarin S.K., Omata M. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatology International (2024). doi:10.1007/s12072-024-10732-z Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102196
Title
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Author(s)
Lau G.
Obi S.
Zhou J.
Tateishi R.
Qin S.
Zhao H.
Otsuka M.
Ogasawara S.
George J.
Chow P.K.H.
Cai J.
Shiina S.
Kato N.
Yokosuka O.
Oura K.
Yau T.
Chan S.L.
Kuang M.
Ueno Y.
Chen M.
Cheng A.L.
Cheng G.
Chuang W.L.
Baatarkhuu O.
Bi F.
Dan Y.Y.
Gani R.A.
Tanaka A.
Jafri W.
Jia J.D.
Kao J.H.
Hasegawa K.
Lau P.
Lee J.M.
Liang J.
Liu Z.
Lu Y.
Pan H.
Payawal D.A.
Rahman S.
Seong J.
Shen F.
Shiha G.
Song T.
Sun H.C.
Masaki T.
Sirachainan E.
Wei L.
Yang J.M.
Sallano J.D.
Zhang Y.
Tanwandee T.
Dokmeci A.
Zheng S.S.
fan J.
Fan S.T.
Sarin S.K.
Omata M.
Obi S.
Zhou J.
Tateishi R.
Qin S.
Zhao H.
Otsuka M.
Ogasawara S.
George J.
Chow P.K.H.
Cai J.
Shiina S.
Kato N.
Yokosuka O.
Oura K.
Yau T.
Chan S.L.
Kuang M.
Ueno Y.
Chen M.
Cheng A.L.
Cheng G.
Chuang W.L.
Baatarkhuu O.
Bi F.
Dan Y.Y.
Gani R.A.
Tanaka A.
Jafri W.
Jia J.D.
Kao J.H.
Hasegawa K.
Lau P.
Lee J.M.
Liang J.
Liu Z.
Lu Y.
Pan H.
Payawal D.A.
Rahman S.
Seong J.
Shen F.
Shiha G.
Song T.
Sun H.C.
Masaki T.
Sirachainan E.
Wei L.
Yang J.M.
Sallano J.D.
Zhang Y.
Tanwandee T.
Dokmeci A.
Zheng S.S.
fan J.
Fan S.T.
Sarin S.K.
Omata M.
Author's Affiliation
Yamanashi Prefectural Central Hospital
Ramathibodi Hospital
Siriraj Hospital
Graduate School of Medicine
Teikyo University Chiba Medical Center
Graduate School of Medicine
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Chinese Academy of Medical Sciences & Peking Union Medical College
Peking University International Hospital
Yonsei Cancer Hospital
Institute of Liver and Biliary Sciences
National University Health System
Sun Yat-Sen University Cancer Center
Zhejiang Shuren University
West China School of Medicine/West China Hospital of Sichuan University
Beijing Friendship Hospital, Capital Medical University
Kaohsiung Medical University Chung-Ho Memorial Hospital
Mongolian National University of Medical Sciences
University of Santo Tomas, Manila
General Hospital of People's Liberation Army
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
The Aga Khan University Hospital
Juntendo University
National Cancer Centre, Singapore
Teikyo University School of Medicine
Zhejiang University School of Medicine
Kagawa University Faculty of Medicine
Yamagata University Faculty of Medicine
The University of Sydney
National Taiwan University College of Medicine
Tsinghua University
Naval Medical University
University of Macau
Harbin Medical University
Sun Yat-Sen University
Tianjin Medical University Cancer Institute & Hospital
Ankara Üniversitesi
Fudan University
Peking Union Medical College Hospital
Bangabandhu Sheikh Mujib Medical University
Faculty of Medicine
The University of Hong Kong
Nanjing University of Chinese Medicine
Hong Kong Sanatorium and Hospital
Chinese University of Hong Kong
The Catholic University of Korea, College of Medicine
Seoul National University College of Medicine
African Liver Patient Association (ALPA)
Fatima University Medical Center Manila
European Liver Patients' Association
Army General Hospital
World Hepatitis Alliance
Humanity and Health Clinical Trial Center
Ramathibodi Hospital
Siriraj Hospital
Graduate School of Medicine
Teikyo University Chiba Medical Center
Graduate School of Medicine
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Chinese Academy of Medical Sciences & Peking Union Medical College
Peking University International Hospital
Yonsei Cancer Hospital
Institute of Liver and Biliary Sciences
National University Health System
Sun Yat-Sen University Cancer Center
Zhejiang Shuren University
West China School of Medicine/West China Hospital of Sichuan University
Beijing Friendship Hospital, Capital Medical University
Kaohsiung Medical University Chung-Ho Memorial Hospital
Mongolian National University of Medical Sciences
University of Santo Tomas, Manila
General Hospital of People's Liberation Army
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
The Aga Khan University Hospital
Juntendo University
National Cancer Centre, Singapore
Teikyo University School of Medicine
Zhejiang University School of Medicine
Kagawa University Faculty of Medicine
Yamagata University Faculty of Medicine
The University of Sydney
National Taiwan University College of Medicine
Tsinghua University
Naval Medical University
University of Macau
Harbin Medical University
Sun Yat-Sen University
Tianjin Medical University Cancer Institute & Hospital
Ankara Üniversitesi
Fudan University
Peking Union Medical College Hospital
Bangabandhu Sheikh Mujib Medical University
Faculty of Medicine
The University of Hong Kong
Nanjing University of Chinese Medicine
Hong Kong Sanatorium and Hospital
Chinese University of Hong Kong
The Catholic University of Korea, College of Medicine
Seoul National University College of Medicine
African Liver Patient Association (ALPA)
Fatima University Medical Center Manila
European Liver Patients' Association
Army General Hospital
World Hepatitis Alliance
Humanity and Health Clinical Trial Center
Corresponding Author(s)
Other Contributor(s)
Abstract
In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored?